Earendil Labs, a U.S. and China-based AI-driven biotech company, raised $787 million in its latest funding round124.
The funding will advance its pipeline of nearly 20 drugs targeting autoimmune diseases and cancer24.
The company has formed major licensing deals with Sanofi24.
This raise reflects investor shifts toward AI-biotech pipelines beyond discovery platforms3.
Reports indicate Earendil is considering a Hong Kong IPO, though not confirmed in available sources.
Sources:
1. https://www.tipranks.com/private-companies/earendil-labs
2. https://www.axios.com/pro/biotech-deals/2026/03/20/earendil-labs-787m-advance-pipeline
3. https://techfront360.com/the-founders-rebuilding-biologics-with-ai-inside-earendil-labs-787m-bet/
4. https://www.biopharmadive.com/news/earendil-labs-financing-ai-biologics-china-sanofi/815336/